The company's portfolio includes Lutathera (lutetium Lu 177 dotatate), a first-in-class radioligand therapy for neuroendocrine tumors, along with diagnostic products including NETSPOT and SOMAKIT. In May 2026, Siemens Healthineers agreed to acquire AAA's diagnostic arm for €200 million, leaving Novartis with only the radiotherapeutics operations.
Cyborg Score Rationale
The company owns Lutathera, a first-in-class radioligand therapy product for neuroendocrine tumors. In January 2024, AAA announced plans to expand manufacturing in Japan and China. However, the May 2026 divestiture of its diagnostic arm represents a strategic shift focusing on core radiotherapeutics.
Top Insights
Focused radiopharmaceutical platform with proven clinical efficacy in neuroendocrine tumors
Recent diagnostic divestiture (May 2026) streamlines operations to radiotherapeutics core
Global manufacturing expansion underway with facilities in Asia-Pacific region
Operates as Novartis subsidiary with access to parent company oncology distribution network